In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
about
Maintaining Genome Stability in Defiance of Mitotic DNA DamageDrugging the undruggables: exploring the ubiquitin system for drug developmentNovel strategies to target the ubiquitin proteasome system in multiple myelomaSpotlight on ixazomib: potential in the treatment of multiple myelomaNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsHomopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingKRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceProteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cellsThe next generation of novel therapies for the management of relapsed multiple myeloma.(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsAn evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.New strategies in the treatment of multiple myeloma.Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsChromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitorsNew developments in the management of Waldenström macroglobulinemiaSmall-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.CCR 20th anniversary commentary: In the beginning, there was PS-341.MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteriaThe 26S proteasome complex: an attractive target for cancer therapyTherapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and DeathInvestigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
P2860
Q26738970-20194D59-46A8-48C8-8470-404A9ACAA232Q26752823-73078340-2CB9-4881-B77F-32E5A45F3305Q26773246-2A61174B-F875-4C3D-8B36-557295BB64C6Q26774440-1336A840-CE8A-41A2-A1CC-FD33A0D04A0BQ26822754-1EF99235-F677-474E-8F7A-5A6AF6F3AFD6Q27677425-61358D08-4A7F-41EC-8E58-B4520B84F2EAQ27853300-07C97D52-4F01-4741-B13A-5898B53F380FQ28395203-EE4044C9-C3B0-46E8-842F-7FC6D1618F54Q28541433-8107AF4B-3248-48D5-A1CF-4FD8632CF26CQ30248534-D6D0FC18-6673-4F97-B334-FD7828FA623DQ30561836-A60A424B-E6AB-41AE-B1B2-85D038105B84Q33409172-852B636D-5033-4049-92A4-3FFA82496D6CQ33415759-AED4DF73-33D9-4D5C-BB36-2DCD10CACE0BQ33415893-C1A9019A-28F3-41DE-86A7-0924B5BFCA83Q33418098-E0B40111-6A5E-4046-B350-6308E02EBF87Q33421241-134F0B38-E078-4C01-9D4B-74401CD428F8Q33425190-ABD217B4-3CC5-478D-96F3-CE2A9E5871AFQ33427510-878A3FB3-FD1D-4628-A4DD-93B3C7250699Q33431175-6B6FA190-6A88-4156-BABC-56545F2F666FQ33601825-080F37C4-9E24-4AF7-975A-DD91CB747B38Q33958520-33173A14-3C42-4327-8F66-F124A64FC110Q34045104-59115679-2743-4BEE-8B70-F8849B97D247Q34218976-6F796150-C5F5-44D7-B74F-6386D3824D0CQ34283680-B78D036F-4076-4EDC-A455-B0A9486A8F67Q34448863-E79CBE09-4357-4AFE-BBF5-8E3E505B01BDQ34532897-ED84F90F-5973-47F0-A751-4F99B77D2BC7Q34553880-1FB34CBB-1985-489A-B64A-FB1F46846D21Q34722352-7B73E081-9D1C-4A76-BF2D-CA47E6FCA5BAQ34773850-17B9ECA4-3E4D-4ACA-AF35-50E06C6CB208Q34778972-DAD8CB32-52B0-4841-9237-13FDEE9A4F61Q34788381-D4E18C51-4563-460D-A8A1-8B139B112102Q35052044-86888F7B-6B05-465F-A6DD-2BF6E0B2E514Q35146095-6B373D2A-19E7-4C28-8F93-576020417460Q35178969-2E532863-AE0F-4C67-913C-4F8A2ED6FAF0Q35538460-C172E65C-FB15-4BAB-A8D2-85E3215D510FQ35620201-9E5171B9-5100-406D-BA97-1E8BCC95AA93Q35624079-42FC3771-F704-4CA8-8BBC-3A6A206060FEQ35895152-1923F794-0DA0-4D66-993D-5ED7FB2CD173Q36104970-3EAD7AA2-59AB-4798-A60B-D610B306AFE4Q36395596-6E565BA6-CB09-4D65-8669-6DA1E1FF04B2
P2860
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vitro and in vivo selective ...... against multiple myeloma cells
@ast
In vitro and in vivo selective ...... against multiple myeloma cells
@en
type
label
In vitro and in vivo selective ...... against multiple myeloma cells
@ast
In vitro and in vivo selective ...... against multiple myeloma cells
@en
prefLabel
In vitro and in vivo selective ...... against multiple myeloma cells
@ast
In vitro and in vivo selective ...... against multiple myeloma cells
@en
P2093
P2860
P50
P1476
In vitro and in vivo selective ...... against multiple myeloma cells
@en
P2093
Deborah Kuhn
Dharminder Chauhan
Noopur Raje
P2860
P304
P356
10.1158/1078-0432.CCR-11-0476
P407
P577
2011-06-30T00:00:00Z